ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements
Alembic Pharmaceuticals Limited has redeemed Commercial Papers (CP) worth Rs. 100 Crores. The redemption was completed on the maturity date of September 25, 2026.
Alembic Pharmaceuticals has redeemed Commercial Papers worth Rs. 150 Crore upon maturity on 23rd September 2026.
Alembic Pharmaceuticals has successfully redeemed Commercial Papers worth ₹150 Crore upon maturity. This confirms the repayment of the company's debt obligation.
Alembic Pharmaceuticals completed an unannounced USFDA onsite inspection at its Vadodara Bioequivalence Facility. The inspection concluded with zero Form 483 observations, a positive regulatory signal.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in the UAE for Rs. 0.26 Crore to explore new business opportunities in pharmaceuticals.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai to explore new business opportunities and distribution.
Alembic Pharmaceuticals Limited has appointed Mr. Chirag Shukla as the Company Secretary and Compliance Officer (Key Managerial Personnel), effective 20th August, 2026.
Alembic Pharmaceuticals' Company Secretary and Compliance Officer, Ms. Manisha Saraf, has resigned from her position effective August 10, 2026.
Q1FY27 revenue grew 26% to INR 2,150 Cr. Strategy focuses on US Generics volume growth, India Specialty therapeutic scale-up, and managing margin dilution from US branded investments.
Alembic Pharmaceuticals held its 16th Annual General Meeting on August 5, 2026. The meeting covered adoption of financial statements, dividend declaration, and director appointments.
Alembic Pharmaceuticals reported Q1 FY27 revenue of Rs. 2,150 Crore, a 26% YoY increase. Net profit rose 12% to Rs. 173 Crore during the period.
Alembic Pharmaceuticals reported a 26% revenue increase to ₹2,150 Crore for Q1 FY27. Profit After Tax grew 12% to ₹173 Crore, driven by strong US growth.
Alembic Pharma delivered strong Q1 FY27 results with 26% revenue growth, driven by a 49% surge in US formulations. Strategy focuses on specialty US branded expansion and peptide development.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,150 Cr (+25.7% YoY) and net profit of ₹173.1 Cr (+12.1% YoY) for Q1 FY27.
Alembic Pharmaceuticals Limited received USFDA final approval for Prucalopride Tablets (1 mg and 2 mg). The product addresses a US$ 100 million market for chronic idiopathic constipation.
Alembic Pharmaceuticals has scheduled a board meeting on August 4, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Alembic Pharmaceuticals' partner NATCO Pharma received USFDA tentative approval for Olaparib tablets (100mg and 150mg). Alembic will distribute the product in the U.S. market.
Alembic Pharmaceuticals received a USFDA Warning Letter regarding Informed Consent Form observations at its Vadodara facility. No operational restrictions or material financial impacts are expected.
Alembic Pharmaceuticals fixed July 29, 2026, as the record date for dividend entitlement. Payments will commence on August 6, 2026, subject to shareholder approval.
Alembic Pharmaceuticals submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report includes a Reasonable Assurance Report provided by Bureau Veritas.
Alembic Pharmaceuticals submitted its Integrated Annual Report for FY 2025-26. The report includes the notice for the upcoming Annual General Meeting.
Alembic Pharmaceuticals issued a notice for its 16th AGM on August 5, 2026. Agenda includes dividend declaration and appointment of an Independent Director.
CRISIL has reaffirmed ratings for Alembic Pharmaceuticals. The ratings cover bank loans and commercial papers totaling ₹2,200 Crore.
Alembic Pharmaceuticals received USFDA final approval for Dapsone Gel, 5%. This marks the company's 224th final ANDA approval.
Alembic Pharmaceuticals received USFDA final approval for Oseltamivir Phosphate Oral Suspension. The product has an estimated market size of ₹253.8 Crore.
Alembic Pharmaceuticals redeemed its Commercial Papers of Rs. 150 Crores on the maturity date. This confirms timely debt repayment, reducing outstanding liabilities.
CARE Ratings reaffirmed Alembic Pharmaceuticals' Commercial Paper rating at CARE A1+. The reaffirmation reflects stable credit quality and no change in outlook.
Alembic Pharmaceuticals Limited redeemed Commercial Papers worth ₹100 Crore on their maturity date. This redemption reduces the company's short-term debt obligations and interest burden.
Alembic Pharmaceuticals executed a Shareholders' Agreement to acquire a 45% stake in a new Canadian corporation. The venture focuses on pharmaceutical commercialization in Canada.
Alembic Pharmaceuticals requested physical shareholders to update KYC and nomination details with MUFG Intime India. Compliance ensures timely dividend credits and prevents withholding per SEBI regulations.